Rating Change
Needham analysts reiterated a Buy rating on Revolution Medicines, Inc. (NASDAQ:RVMD) on July 20, 2026.
reiterateNASDAQ:RVMD
Needham Reiterates Buy Rating on Revolution Medicines, Inc. (RVMD)
Rating Change Needham analysts reiterated a Buy rating on Revolution Medicines, Inc. (NASDAQ:RVMD) on July 20, 2026. Market Context Revolution Medicines, Inc.
Market Context
Revolution Medicines, Inc. operates in the Healthcare sector. The stock currently trades at $185.34 with a market capitalization of $15.2B. The stock has gained 386.4% over the past 52 weeks.
Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Revolution Medicines, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Revolution Medicines, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 20, 2026 | Needham | Buy | N/A |
| Jul 09, 2026 | Guggenheim | Buy | N/A |
| Jul 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 06, 2026 | Mizuho | Outperform | N/A |
| Jul 02, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View RVMD Stock Page
Frequently Asked Questions
What does a Buy rating mean for RVMD?
A Buy rating from Needham reflects the analyst's outlook on Revolution Medicines, Inc. (NASDAQ:RVMD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RVMD forecast page.